NCT04885621

Brief Summary

This pilot study will involve intensive training in self-management of diabetes mellitus. The intensive diabetes self-management program will involve an initial diabetes assessment with the nurse/diabetes educator, an initial evaluation by the Endocrinologist, Dr. Santen, at one of the Tri-Area CHC clinics; weekly or bi-weekly phone calls to review glucose and insulin data and 3-month, 4.5 month and 6-month follow-ups on telemedicine with Dr. Santen. A cloud based glucose monitoring system will utilize the Verizon based Telcare glucose meter with glucose test strips and the Glucommander-outpatientR algorithm to make insulin dosage recommendations. The goal will be to test blood glucose 4-7 times/day. The serial glucose levels are accessible on the meter itself but also can be accessed online by the entire diabetes team. Weekly to four weekly phone calls with the UVA endocrinologist ( and nurse/diabetes educator from Tri-Area as necessary) will be completed to discuss glucose patterns and make insulin adjustments. In addition, the patient will attend four diabetes tele-education programs to learn more about improved self-management of their diabetes. To facilitate nutritional education, a modified , patient specific, Nutrisystem R diet will be supplied , designed to be the exclusive source of nutrition. This diet will involve 1200 calories for women and 1800 calories for men. Both frozen and non-frozen food will be delivered to the patient. Nutrisystems will supply these " meal replacements" at a reduced cost based on this pilot program.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2021

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

May 8, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 13, 2021

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2023

Completed
Last Updated

December 21, 2023

Status Verified

December 1, 2023

Enrollment Period

2.4 years

First QC Date

May 8, 2021

Last Update Submit

December 20, 2023

Conditions

Keywords

nutrisystemsdiabetes mellitusunderserved patientsglucomander-outpatienttelcare

Outcome Measures

Primary Outcomes (1)

  • hemoglobin A1C levels

    measurement of average glucose levels over time

    six months

Secondary Outcomes (2)

  • lipid levels

    6 months

  • Weight/BMI

    6 months

Study Arms (1)

underserved patients with diabetes mellitus

patients with type 2 diabetes mellitus living in underserved, financially challenged areas of Southwest Virginia who are poorly controlled

Dietary Supplement: nutrisystem-D

Interventions

nutrisystem-DDIETARY_SUPPLEMENT

Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions

Also known as: Glytec glucomander-outpatient
underserved patients with diabetes mellitus

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

poorly controlled diabetes mellitus

You may qualify if:

  • Hemoglobin A1C \> 8.0 on two occasions renal function at least 50% of normal persistent, poorly controlled diabetes -

You may not qualify if:

  • alcohol/substance abuse, active cancer therapy, HIV/AIDS, organ transplant, cirrhosis of liver, hearing or speech impediment, dementia or psychosis, cannot speak English or interact appropriately with interpreter

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Virginia

Charlottesville, Virginia, 22908, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Emeritus Professor of Medicine

Study Record Dates

First Submitted

May 8, 2021

First Posted

May 13, 2021

Study Start

May 1, 2021

Primary Completion

September 15, 2023

Study Completion

September 15, 2023

Last Updated

December 21, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations